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Abstract
Introduction: Genome-wide association studies have led to numerous genetic loci
associated with Alzheimer’s disease (AD).Whole-genome sequencing (WGS) now per-
mits genome-wide analyses to identify rare variants contributing to AD risk.
Methods: We performed single-variant and spatial clustering–based testing on rare
variants (minor allele frequency [MAF]≤1%) in a family-basedWGS-based association
study of 2247 subjects from605multiplex AD families, followed by replication in 1669
unrelated individuals.
Results:We identified 13 new AD candidate loci that yielded consistent rare-variant
signals in discovery and replication cohorts (4 from single-variant, 9 from spatial-
clustering), implicating these genes: FNBP1L, SEL1L, LINC00298, PRKCH, C15ORF41,
C2CD3, KIF2A, APC, LHX9, NALCN, CTNNA2, SYTL3, and CLSTN2.
Discussion: Downstream analyses of these novel loci highlight synaptic function, in
contrast to common AD-associated variants, which implicate innate immunity and
amyloid processing. These loci have not been associated previously with AD, empha-
sizing the ability of WGS to identify AD-associated rare variants, particularly outside
of the exome.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and nomodifications or adaptations aremade.
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1 INTRODUCTION
Alzheimer’s disease (AD) is the most common neurodegenerative dis-
order and one of the most challenging societal problems in the indus-
trialized world. Susceptibility to AD is determined by both monogenic
and polygenic risk factors aswell as by environmental exposure.Mono-
genic AD most often presents as early onset (<60 years) familial AD
(EOFAD), constituting less than 5% of all cases, and caused by any of
hundreds of very rare mutations in at least three genes: amyloid pre-
cursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2).
Most AD cases are sporadic or familial late onset (>60 years) AD
(LOAD) and are characterized by both a complex polygenic background
and nongenetic factors. The identification of genetic determinants
underlying polygenic AD has been the aim of more than 1000 genetic
association studies,1 including more than 75 genome-wide association
studies (GWAS) on AD and related traits as outcomes (according to
European Bioinformatics Institute’s (EBI) GWAS catalog). The largest
AD GWAS3 to date was conducted on over 600,000 individuals with
an AD-by-proxy phenotype and highlighted a total of 29 independent
genome-wide significant (P < 5×10–8) AD risk loci.4 Another recent
GWASbyKunkle et al.5 found 25 loci in their analyses of clinically diag-
nosed LOAD in over 90,000 individuals. Essentially, these and other
ADGWAS focused on common (typically with a minor allele frequency
[MAF] ≥1%) variants either directly assayed or imputed using high-
density reference panels. The few exceptions to these common-variant
studies utilized either microarray-based or next-generation sequenc-
ing (NGS)–based genotyping limited to exonic variants and identified
rare (MAF <1%) missense variants either increasing (TREM2, PLCG2,
ABI3, ADAM10) or decreasing (APP, CD33) risk for AD.6–9
In this study we used deep (> 40x) whole-genome sequencing
(WGS) to search for novel AD variants in 2247 individuals from 605
multiplex AD families from the National Institute on Mental Health
(NIMH)10 and National Institute on Aging (NIA) Alzheimer’s Disease
Sequencing Project (ADSP)11 data sets. Analyses were focused on rare
variants withMAF<1% (based on the non-Finnish European subset of
gnomAD v3.0,12 unless stated otherwise) and entailed single-variant
and spatial clustering–derived (ie, “region-based”) testing. Suggestive
findings (P < 5×10–4) were validated in publicly available WGS (NIA
ADSP case-control population13) data on more than 1650 indepen-
dent AD cases and controls. In total, we highlight four single-variant
and nine region-based findings exhibiting consistent rare-variant
association with AD across the discovery and replication phases in our
study. None of the newly implicated loci were highlighted previously in
any of the common-variant ADGWAS. Functionally, our results extend
existing knowledge on the underlying disease pathways highlighted
by common variants and converge upon a role for neuroplasticity and
synaptic function, emphasizing the power of WGS in the context of
rare-variant–based gene discovery efforts.
2 RESULTS
2.1 Description of general sequencing metrics
After sample quality control (QC) (seeMethods),WGS data from 2247
individuals (NIMH n = 1393 and NIA ADSP families n = 854); here-
after referred to as the “discovery sample” (Supplementary Table 1;
see Figure 1 for an overview of the study design) were available for
subsequent analyses. Median read depth across the genome in NIMH
was 40.4-fold (mean 41.2). Within the discovery sample, we identified
a total of 54,669,406 sequence variants, of which 40,542,616 were
listed in the non-Finnish European subset of the Genome Aggrega-
tion Database (gnomAD12; v3.0, n= 32,399, Supplementary Figure 1).
Of these, 907,273 (2%) were located in protein-coding exons (Supple-
mentary Figure 2). Of all identified variants, the vast majority, that is,
31,200,539 (77%) were “rare” (MAF ≤1%), whereas 2,855,054 (7%)
were “low-frequency” (≤5% MAF >1%), and 6,487,023 (16%) were
“common” (MAF > 5%). Overall, we captured a large proportion of the
“common” (95.8%) and “infrequent” (90.9%) variant space, using gno-
mAD as reference. As expected, the captured proportion was smaller
for “rare” variants (11.7%), which can be attributed to the differ-
ence in sample sizes. After variant QC (Methods), 18,263,694 variants,
11,012,452, of which were rare, were used in subsequent analyses.
2.2 Single-variant AD association results
To probe for association between single markers and AD status, we
used the FBAT Toolkit14 in the family-based discovery data set and
logistic regression in the case-control replication data (Methods).
These analyses revealed a total of 24,301 rare variants showing asso-
ciation with AD at P < 0.01. As can be seen from the corresponding
QQ plot (Figure 2), we observed a deflation of test statistics starting
from P < 0.05. This deflation can be attributed to the fact that the
FBAT statistics is conservative in the case of a small number of infor-
mative families and/or low allele frequencies. Of the variants showing
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F IGURE 1 Data analysis workflow
association at P < 0.01, none have reached conventional genome-
wide significance (ie, P < 5×10–8). A total of 271 variants attained
P < 5×10–4 (Supplementary Table 2) and were prioritized for valida-
tion assessments in the independent WGS case-control data set (NIA
ADSP non-Hispanic whites (NHW), ntotal= 1669 (ncases= 983), here-
after referred to as “replication data set”; Figure 1). These assessments
converged on two variants in two regions (rs74065194≈200 kb down-
stream from SEL1L [MAF = 0.0066; Pmeta = 0.011] and rs192471919
intronic of FNBP1L [MAF = 0.0054; Pmeta = 0.017]) to show at least
nominal replication with the same direction of effect as in the discov-
ery datasets (Figure 3a, Supplementary Figure 3-4, Table 1a). Notably,
rs192471919 had a nominally significant association (P = 0.008), with
same effect direction in Jansen et al.3 where it was present only in
the PGC-ALZ cohort (n = 16,350). In addition, we highlight four vari-
ants that yielded P = 0.000538, that is, just above our screening
threshold, located ≈100 kb downstream of STK31 (MAF = 0.0067;
Pmeta = 0.0035) (Supplementary Figure 5).
In a second filtering paradigm, we selected variants showing
consistent (ie, Pdiscovery< 0.05 and the same direction of effect in
discovery and replication data sets) association at P < 0.0005 fol-
lowing meta-analysis. This revealed three additional single variant
associations in two loci (ie, rs147918541 intronic of LINC00298
and ≈700 kb upstream of ID2 (MAF = 0.0072; Pmeta = 2.44×10
–4),
and rs147002962 and rs141228575, both intronic of C15orf41
(MAF=0.0069;Pmeta=3.03×10
–4); Figure3B; Table1b). Furthermore,
we assessed the recently described9 “exome-chip”-based rare-variant
genome-wide and suggestive association signals (Supplementary
Table 3). This revealed significant association with one of the two
TREM2 variants (rs75932628 (MAF = 0.0021; Pmeta = 0.0329) as well
as suggestive support for rs72824905 in PLCG2 in the discovery sam-
ple only (MAF= 0.0087; Pdiscovery = 0.0546, Pmeta = 0.259). In contrast,
we did not observe evidence for an associationwith the second TREM2
variant (rs143332484) or rs616338 in ABI3 in either the discovery or
the replication samples. In addition, one HGFAC variant (rs114303452
(MAF = 0.012; Pdiscovery = 0.026, Pmeta = 0.7) from the extended set
of suggestive variants, reported in Sims et al., was significant in our
RESEARCH INCONTEXT
1. Systematic review: We performed an extensive litera-
ture review from PubMed and preprint servers, such
as biorxiv and medrxiv. Previous work has established
AD-associated loci using either genotyping and imputa-
tion or whole exome sequencing. Few studies with whole
genome sequencing data with limited sample sizes have
been reported. This article is the first and, to the best
of our knowledge, the currently largest systematic WGS-
based genetics study in the AD field.
2. Interpretation: We highlight 13 rare-variant signals (4
from single-variant, 9 from spatial-clustering analyses)
exhibiting association with AD across the discovery (fam-
ilies) and replication (case-control) cohorts and related to
synaptic function and neuronal development.
3. Future directions: These results should be confirmed in
additional data sets and using biological validation. Addi-
tional research is needed in clarifying the role of rare
variants in non-coding regions. Currently, our results sug-
gest different functional pathways (neuronal/synaptic)
for rare variants, as compared to common-variant func-
tional assignments (microglial/innate immunity).
discovery sample only. Finally, we identified at least 786 nominally
(P< 0.05) significant rare-variant signals in genes corresponding to loci
previously associated with AD in common-variant GWAS3,5 (Supple-
mentary Table 4), suggesting that at least some of the common-variant
signals in these loci can be attributed to rare sequence variation (in
line with earlier findings15,16). For comparison, we also plotted single-
variant association results in the discovery cohorts without MAF
restriction, that is, for both rare and common variants (Supplementary
Figure 6 and Supplementary Fig. 7) and compared these with the 29
GWASSNPs from Jansen et al.3 (Supplementary Table 5) and 25GWAS
SNPs from Kunkle et al.5 (Supplementary Table 6). As expected, these
analyses revealed a pronounced, genome-wide significant (P<5×10–8)
signal with markers in the apolipoprotein E (APOE) region on chromo-
some 19q13 as well as suggestive signals with several of the other
common-variant GWAS signals, such as BIN1, TREM2, CD2AP, PICALM,
and ALPK2. In addition, we observed a borderline genome-wide signif-
icant signal driven by low frequency variants in PTPRN2 (rs17837786:
MAF= 0.043; Pdiscovery = 1.36×10
–7, Pmeta = 0.187); however, this sig-
nal was not replicated in the case-control data set.
2.3 Spatial-clustering AD-association results
Our second analysis arm computed aggregated results on consecutive
runs of rare variants in the discovery data set. In principle, this is similar
to “gene-based” testing (such as performedbyVEGAS17 orMAGMA18)
1512 PROKOPENKO ET AL.
TABLE 1 Top single-variant AD association results
a b
Chromosome 14 1 7 2 15








Nearest protein-coding gene SEL1L FNBP1L STK31 LINC00298 C15orf41
Allele frequency, non-Finnish Europeans,
gnomAD v3
0.0065 0.0054 0.0067 0.0072 0.0069




Z-score 3.551 -3.485 -3.461 -1.98 2.048
P-value 3.84E-04 4.93E-04 5.38E-04 4.78E-02 4.06E-02
NINFF 9 6 7 4 7
Replication dataset
NHWADSP
Z-score 2.275 -2.182 -2.698 -3.576 3.488
P-value 2.29E-02 2.91E-02 6.97E-03 3.49E-04 4.86E-04
Sample size 1669 1669 1668 1669 1669
Meta-analysis Effect
direction
++ -- -- -- ++
Z-score 2.529 -2.387 -2.916 -3.668 3.613
P-value 1.14E-02 1.70E-02 3.54E-03 2.44E-04 3.03E-04
Jansen et al. Z-score 1.134 -2.656 -0.319 NA -0.919
P-value 2.57E-01 7.92E-03 7.50E-01 NA 3.58E-01
Kunkle et al. Z-score 1.181 NA 1.589 NA -0.571
P-value 2.37E-01 NA 1.12E-01 NA 5.68E-01
UCSC All mRNA 0 13 3 7 6
UCSC/ENCODE TFBS clusters 1 0 0 0 0
GWAVA DNase cluster 0 0 9 0 1
Ensembl TFBS 0 0 118 0 0
GWAVA GC content 0.45 0.4 0.57 0.33 0.43
Location Upstream Intronic Downstream Intronic Intronic
Mayo cohort Expression in
AD temporal
cortex









































Overlapping/GREAT-assigned genedid not differ from thenearest gene assignment. For comparison, results fromJansen et al. (2019) andKunkle et al. (2019)
are included. NINFF - number of informative families, TFBS - transcription factor binding site.
a: Single-variant AD association results with P < 0.0005 (P < 0.0006) in the discovery dataset and consistent (ie, P < 0.05 and same direction of effect)
association in the ADSPNHWWGS replication dataset.
b: Single-variant AD association results with consistent (ie, Pdiscovery< 0.05 and same direction of effect in discovery and replication dataset) association at
P< 0.0005 after meta-analysis.
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F IGURE 2 QQplot of rare (MAF<= 1%)
single-variant association results in the
family-based discovery data set (NIMH andNIA
cohorts). The red line corresponds to all
statistics, where at least one informative family
is observed. The green line corresponds to
statistics with at least ten informative families
except the approach applied here19 utilizes all available variants,
including those located between genes that are otherwise typically
omitted from this type of analysis, for example, VEGAS. These analy-
ses revealed a total of 1756 regions showing an association with AD at
P < 0.01; however, no region reached a Bonferroni threshold level of
P < 2.15×10–7 (for a Manhattan and QQ plot of all spatial-clustering-
based rare-variant results see Figure 4A and B and Figure 5). Using
P<5×10–4 as a suggestive threshold yielded signals in47 regions in the
discovery data sets (Supplementary Table 7), 4 of which also showed at
least nominal evidence for independent replication in the NHWADSP
data set (PRKCH [Pmeta = 8.17×10
–6], C2CD3 [Pmeta = 5.12×10
–5],
KIF2A [Pmeta = 1.00×10
–4], APC [Pmeta = 1.79×10
–4]; Table 2a, Supple-
mentaryFigure8-11). A further six (five ofwhichwerenovel) candidate
gene regions (PRKCH, LHX9,NALCN,CTNNA2, SYTL3,CLSTN)werehigh-
lighted in the secondary analyses focusing on topmeta-analysis results
(Pmeta< 5×10
–5 and Pdiscovery < 0.05) only, yielding association signals
with P-values ranging from 3.27×10–5 to 8.17×10–6 (Table 2b).
Next, using our discovery WGS data set, we checked recently
described burden rare variant associations with AD from a large WES
study.20 By implementing a similar filtering scheme in exons and split-
ting the case-control phenotype into three categories (Methods), we
identified nominally significant associations in ABCA7 (P = 0.016),
TREM2 (P = 0.025) and SORL1 (P = 0.039) (Supplementary Table 8).
Wealso note thatmanydamaging rare variantswere absent in our data
set due to the lower sample size.
Finally, we also performed gene-based burden testing on rare vari-
ants in knownADgenes (ie,APP,PSEN1,PSEN2aswell as those recently
highlighted as genome-wide significant loci inGWAS (Jansenet al.3 and
Kunkle et al.5). This revealed two nominally significant association sig-
nals in ZCWPW1 (P= 0.028) and PICALM (P= 0.03), and two suggestive
association signals in ALPK2 (P= 0.053) andMS4A6A (P= 0.084), upon
meta-analysis (Supplementary Table 9).
For comparison, we also plotted spatial clustering–based associ-
ation results without MAF restriction in the discovery cohorts, that
is, for both rare and common variants and, as expected, the top-
associated region in these analysesmaps to theAPOE locus on chromo-
some 19q13.32 (Supplementary Figure 12 and 13, and Supplementary
Table 10).
Taken together, our WGS-based association results revealed 13
novel potential AD loci (4 from single-variant, 9 from spatial-clustering
analyses) with consistent rare-variant signals in both discovery and
replication cohorts. It is important to note that none of the identi-
fied loci have been highlighted previously in any common variant or
WES/exome-chip association study in the field, emphasizing the added
resolution and power afforded by genome-wide sequencing performed
outside coding regions. Notwithstanding, some of the loci highlighted
here may reflect spurious associations due to type I error; thus any
future consideration of our results should await further validation in
independent samples.
2.4 In silico functional implications of the
single-variant association findings
The leading single nucleotide variant (SNV) associations from the dis-
covery (Table 1a) and themeta-analysis (Table 1b) include rs74065194,
which is upstream of SEL1L, located within a transcription factor–
binding site cluster. The SNVrs192471919 is situatedwithin the intron
of FNBP1L and open chromatin specific to the brain cingulate gyrus,
liver cells, and monocytes. Three SNVs are intronic to LINC00298
(rs147918541), a long non-coding RNA gene expressed mostly in
brain, and C15orf41 (rs147002962; rs141228575) which is expressed
mostly in heart. The four variants assigned to STK31, which almost



















TABLE 2 Top spatial clustering–based AD association results
a b
Chromosome 14 11 5 5 14 1 13 2 6 3
Position of the first SNV 61176726 74025114 61972635 112819545 61176726 197917553 101143359 79853746 158677635 140398927
Position of the last SNV 61188023 74031365 61975793 112827357 61188023 197929226 101164882 79856892 158683441 140449630






53 47 13 25 53 44 106 15 29 233





53 42 16 29 53 39 134 18 28 273
P-value 2.11E-02 4.54E-02 4.65E-02 4.37E-02 2.11E-02 1.31E-04 4.27E-04 1.54E-01 1.16E-04 1.96E-01
Meta-analysis P-value 8.17E-06 5.12E-05 1.00E-04 1.79E-04 8.17E-06 1.48E-05 1.63E-05 2.67E-05 2.90E-05 3.27E-05












Mayo Expression in AD
temporal cortex































FANTOM TFBS 86 0 0 0 86 429* 0 0 0 0
FANTOM Transcription
start sites
6 3 0 5 6 24 2 0 0 9
Ensembl BindingMotifs 14 0 0 0 14 1 2 1 0 7
Ensembl Active enhancer 10 0 0 10 10 0 26 6 0 32*
Ensembl Open chromatin
region active
0 0 0 0 0 0 1 0 1 2
Ensembl Active promoter 61* 15 0 0 61* 104 0 0 0 57
Ensembl Active TFBS 0 0 0 0 0 15* 19* 0 0 0
Ensembl CTCF binding site
active
9 2 0 0 9 31 73* 19 0 16
UCSC Cell-specific TFBS 81 12 4 15 81 117 31 7 6 40
UCSC CpG islands 0 0 0 0 0 2 0 0 0 0
UCSC DNase cluster 17 8 1 5 17 15 18 3 3 44
The PRKCH region was identified in both arms of the regional study, hence appears in both: a and b. Overlapping/GREAT-assigned gene did not differ from the nearest gene assignment. SNV - single nucleotide
variant, TFBS - transcription factor binding site,WBC - white blood cells. *Significantly more annotations than expected by chance after correcting for multiple testing.
a: Replicated spatial clustering–based AD association results for regions showing P< 0.0005 in the discovery data set.
b: Top spatial clustering–based AD association results based onmeta-analysis (Pmeta < 5×10
-5 and Pdiscovery < 0.05).
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F IGURE 3 Manhattan plot of rare (MAF<= 1%) single-variant association results in the family-based discovery data set (NIMH andNIA
cohorts). Genes that correspond to replicated variants as described in the workflow (Figure 1) are highlighted
the temporal cortex of AD patient samples when compared to con-
trols (Padj. = 1.1×10
–5). Of these SNVs, rs112941445 is the most likely
to be the causal variant given that it has the most epigenetic support
(Table 1a).
The most highly significant SNV-associated meta-analysis gene was
LINC00298. This long intergenic non-coding RNA (lincRNA) has no
known function. Of the 73 rare variant–associated genes co-expressed
with LINC00298 in our study, 17 are included in protein-protein
interactions with our newly AD-associated genes, including APC (corr
0.449) and CTNNA2 (corr 0.381) (Figure 6), and also the known AD
and frontal lobe dementia–associated gene encoding tau protein,
MAPT (corr 0.379). Functional enrichment for LINC00298-correlated
expression of genes found in our study results in one significant
enrichment for the HIPPO signaling pathway (Padj. = 2.2×10
–7; Supple-
mentary Table 11) andweaker correction-adjusted significance for GO
processes synapse organization, spindle formation, cell-cell adhesion, and
neuron projection morphogenesis.
Functional enrichment of the genes associated with the highest-
ranked 1000 SNVs from the meta-analysis (Supplementary Table 12)
identified 151 processes and pathways after correcting for multiple
testing. The most highly enriched terms included flavonoid glucuronida-
tion (Padj. = 1.09×10
–7) (involved in removal of xenobiotics), and many
neuroplastic/developmental-associated processes including synapse
organization (Padj. = 1.32×10
–7), axon guidance (Padj. = 6.51×10
–6),
development and elongation, and also cell adhesion (Padj. =0.001; Supple-
mentary Table 13). Only two pathways were significantly co-enriched
with the GO/pathway gene set enrichment for genes associated with
common variants reported in the GWAS by Jansen et al.3: cell adhe-
sionmolecules and herpes simplex infection (Supplementary Table 14).
In contrast to the broad diversity of functions, such as immune-related
1516 PROKOPENKO ET AL.
F IGURE 4 Manhattan plot of spatial clustering association results based on rare (MAF<= 1%) variants in the family-based discovery data set
(NIMH andNIA cohorts). Highlighted are genes, which correspond to replicated regions, described in the workflow (Figure 1)
and amyloid processing, found to be enriched by genes annotated in
the GWAS by Jansen et al.,3 10 of the 21 top-level functions show-
ing enrichment in our rare-variant analysis had roles related to the
maintenance anddevelopment of neurons, cardiac tissue and synapses,
and neuroplasticity-related terms including synaptogenesis, activity
and synaptic integrity, neurogenesis, sensory organ development, cardiac
development, tissue morphogenesis, and limb development. None of the
enriched pathways, here, exhibited amyloid or immune-related roles.
2.5 In silico functional implications of the
spatial-clustering association findings
Four of the nine leading regions associated with AD are significantly
enriched for regulatory annotation (Table 2). The CLSTN2 and PRKCH
regions are respectively enriched for enhancers and promoters across
a number of cell types, whereas the LHX9 and NALCN loci significantly
overlap with transcription factor binding sites. NALCN additionally is
enriched for active CTCF binding sites. Unlike the SNVs, these nine
regionsmostly cover intronic and exonic locations. The four genesAPC,
CTNNA2, KIF2A, and NALCN are all primarily expressed in brain tissue,
whereasPRKCHexpression is significantly reduced in the temporal cor-
tex of patients with AD (Padj. = 0.0001).
Functional enrichment of genes associated with the highest-
ranked 1000 spatial clustering–based results (Supplementary
Table 15) revealed 127 significantly enriched pathways after cor-
recting for multiple testing. The most highly enriched terms included
neuron projection guidance (Padj. = 1.6×10
–5), kidney development
(Padj. = 2.32×10
–5), cell-cell adhesion (Padj. = 6.53×10
–5), negative
chemotaxis (Padj. = 2.17×10
–4), brain development (Padj. = 4.23×10
–4),
and synapse organization (Padj. = 7.02×10
–4). Seven of the 20 most
enriched terms were related to development, and 81 of the total
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F IGURE 5 QQplot of spatial clustering association results based
on rare (MAF<= 1%) variants in the family-based discovery data set
(NIMH andNIA cohorts)
significantly 127 enriched terms were related to development or neu-
roplasticity (Supplementary Table 16). Meanwhile, no process of 422
was significantly enriched in common with the study of Jansen et al.3
Protein localization to membrane (Padj. = 0.0126, Jansen, Padj.= 0.0631,
regional gene set; Supplementary Table 17) was the closest to reaching
significance.
2.6 Common functional themes between
single-variant and regional analysis
A total of 90 genes were found in common between the most highly
ranked 1000 single-variant and regional findings. These include the
three highlighted genes LINC00298, SEL1L, and STK31 and genes
that rank highly in both gene lists: ROBO1, PRDM9, LINC02439, and
TMEM132C. One hundred fifty-two processes and pathways reached
significance for the co-enrichment of regional- and SNV-associated
genes. The top five terms enriched were positive regulation of nervous
system development (Padj. = 0.0025, SNV; Padj. = 0.000079, regional),
heart development (Padj. =0.0015, SNV; Padj. =0.0039, regional), sensory
organ development (Padj. = 0.0005, SNV; Padj. = 0.01, regional), trans-
synaptic signaling (Padj. = 0.0015, SNV; Padj. = 0.0031 regional), and
tissuemorphogenesis (Padj. =0.002, SNV;Padj. =7×10
–5 regional). Of the
19 significantly co-enriched terms, 10 were related to development
or neuroplasticity; the remainder addressed maintenance and cellular
activity–related functions such as cell-cell adhesion, negative chemo-
taxis, signaling by receptor tyrosine kinases, and organelle localization
(Supplementary Table 18; Supplementary Figure 14).
To investigate the impact of selecting only variants within tran-
scribed gene boundaries on the functional enrichment results, we
restricted our analysis to only those SNVs and regions occurringwithin
a gene transcript, that is, intronic or exonic variants. The most highly
enriched categories (Padj. <= 0.035) included organelle localization, cell-
cell adhesion, cell morphogenesis in neuron differentiation, synapse organi-
zation,modulation of chemical transmission, and protein localization to the
centrosome (Supplementary Figure 15).
2.7 Identification of cell-specific signatures
To assess whether our prioritized variants show an association with
single cell–restricted states, we applied an Expression Weighted Cell
Type Enrichment (EWCE) test21 to genes from our prioritized SNV and
regional analysis results. EWCE is used to predict the primary cell ori-
gins of a disease. Using single-cell mouse data, primarily from the hip-
pocampus and hypothalamus, we discovered an enriched signal of our
SNVs in pyramidal CA1 neurons (Supplementary Table 19). In contrast,
common loci associated with AD22 have been enriched significantly in
microglia (Figure 7).
2.8 Network generation of shared functions and
relationships with known AD-associated genes and
processes
Using known protein-protein interactions as a guide, a network of
interactions was constructed between a total of 1274 interacting pro-
teins, which include known AD-associated genes,22 our single-variant,
and regional-associated genes. Of the 14 leading genes we pinpointed
in this study, 8 (protein-coding) were linked directly by protein-protein
interaction to additional AD-associated genes discovered within this
study or to 21 known AD-associated genes in a subnetwork (Figure 6).
Highlighted genes that interact with known AD genes include FNBP1L,
which interacts directly with the validated GWAS AD genes, PICALM
and BIN1, as well as KIF2A, which interacts directly with the AD gene
HLA-DRB1. Seventeen genes in the subnetwork also co-express with
the highlighted gene, LINC00298.
Functional enrichment of the subnetwork of directly interacting
proteins revealed 196 enriched GO process/KEGG pathway terms
(Supplementary Table 20). The three highest ranked GO processes
(nervous system development, 236 genes, FDR 1.32×10–9; neurogene-
sis 168 genes, FDR 4.74×10–7; developmental process, 460 genes, FDR
3.74×10–7) reflected neuroplasticity/developmental processes of 90
processes enriched for development, differentiation, or biogenesis.
Neurogenesis, a GO process term that annotates 1519 genes, was co-
enriched with PRKCH, LHX9, and CTNNA2 from our pinpointed genes,
and SORL1, PICALM, CNTNAP2 and APOE, and BIN1 from our reference
list of known AD genes (PICALM is a known AD gene also discovered in
our top 1000 regional analysis-associated genes). Co-expression anal-
ysis using pathway co-activation mapping (PCXN23) revealed that ner-
vous system development and several of the associated enriched GO
terms show significant correlated gene expression activity, even when
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F IGURE 6 Network of direct interactions between highly ranked SNV and regional genes and known AD-associated genes. Direct
protein-protein relationships (blue links) between reference AD genes (red), Table 1 and Table 2 (yellow), Supplementary Table 12 and 15 (blue)
protein-coding genes. LINC00298 co-regulated expression of directly interacting genes is highlighted (turquoise border). Proteins that are in direct
interaction with genes from Tables 1 and 2 have been groupedwhere possible according to shared GObiological processes (green ellipse). Proteins
that may not be directly interacting but are found commonly enriched in immune-related processes are grouped (pink square). Proteins with dark
green–colored borders are enriched in GO:BP nervous system development, whereas a navy blue border is enriched for generation of neurons.
Gene-gene relationships are listed in Supplementary Table 24. The network can be interactively explored via the NDEX project website106
there was low gene overlap between enriched term gene sets (Supple-
mentary Table 21).
3 DISCUSSION
Based onWGS of 2247 subjects from 605 multiplex AD families and a
case-control cohort of >1650 individuals, we have identified 13 rare-
variant signals (four from single-variant, nine from spatial-clustering
analyses) exhibiting associationwithADacross the discovery (families)
and replication (case-control) cohorts. Our work represents one of the
first and, to thebest of our knowledge, the currently largest, systematic
WGS-based genetics study in the AD field. In AD, we are only aware of
two published WGS-based studies,24,25 both utilizing different analy-
ses paradigms and much smaller sample sizes. Of note, data from the
latter of theseWGS projects were utilized in the current study for pur-
poses of independent replication.














































































































































F IGURE 7 Cell-specific enrichment results from the EWCE tool.
We compared genes identified in our rare-variant analysis to common
variants published in AD22 andwhich cell type each is significantly
enriched in. Zero represents themean expression in each cell based on
10,000 permutations of gene lists of the same size. The data for this
figure can be found in Supplementary Table 19
The top signals emerging from our single variant–associated anal-
yses were associated with the genes FNBP1L and SEL1L (and STK31),
whereas the secondary analysis pointed to LINC00298 and C15orf41.
All genes directly overlapped with the single variant associations
except for SEL1L, which encodes the suppressor/enhancer of lin-12-
like (Sel1L) adaptor protein for an E3 ligase involved in endoplasmic
reticulum-associated degradation (ERAD) for protein quality control.
Of interest, ERAD has been reported to regulate the generation of
amyloid beta (Aβ) by gamma secretase.26 Deficiency of SEL1L has also
been shown to activate ER stress and promote cell death.27 In addition,
an SNV in intron 3 of SEL1L has previously been reported to confer sus-
ceptibility to AD.28
The FNBP1L gene, which encodes the formin-binding protein 1-like
protein, has been associatedwith adult29 and childhood intelligence.30
FNBP1L has also been reported to be essential for autophagy of
intracellular pathogens, such as Salmonella typhimurium, which serves
to curb intracellular growth.31 This is particularly interesting given
the emerging evidence for the role of microbes in driving AD
neuropathology.32 FNBP1L, also knownas TOCA-1, is implicated in neu-
rite elongation and axonal branching.33 Thus FNBPL1may play a role in
neuroplasticity-related AD pathology.
The STK31 gene encodes the cell cycle kinase, serine/threonine
kinase 31, which is known to promote PDCD5-mediated apoptosis in
p53-dependent human colon cancer cells.34 It is tempting to speculate
as to whether this kinase might also affect phosphorylation of tau and
neurofibrillary tangle formation in AD. However, we note that variants
in this gene technically did not fulfill the significant thresholds and are
highlighted here as additional results.
LINC00298 is a long intergenic non-coding RNA and does not code
for a protein. Its functional role is not known,35 but it exhibits CNS-
specific expression, with a 50-fold and 24-fold enrichment in the ner-
vous system and brain samples in FANTOM 5 CAT (P = 2.9×10-23 and
4.6×10-21, respectively).36 It contains an experimentally supported
target for the brain-expressed non-coding miRNA mir-7,37 which has
been associated with AD and other brain diseases.38,39 LINC00298
can be more broadly functionally characterized by where and when
it is expressed and the genes with which its expression is correlated.
LINC00298 is co-expressed with 33 SNV-associated, and 40 regional-
associated genes (lnchub40). LINC00298’s co-expressed genes appear
to be enriched for developmentally associated processes: Its bias for
expression in the brain; its association with HIPPO pathway, which has
a role in development; co-expression with genes involved in neuronal
differentiation; and expression in neuronal induced pluripotent stem
cells (iPSC) suggest that one of its rolesmay be in regulation involved in
neuronal plasticity. C15orf41 encodes the codanin 1-Interacting nucle-
ase gene (CDIN1), which is highly expressed in the heart, with much
lower expression in the brain.CDIN1 is associatedwith erythrocyte dif-
ferentiation and has genetic associations with congenital dyserythro-
poietic anemia type I.41
Spatial clustering–based analyses highlighted a total of four inde-
pendent genomic regions (Table 2a). One of these regions was in the
gene encoding the protein kinase C receptor eta subunit (PRKCH).
Of interest, we have previously reported three highly penetrant rare
mutations in another protein kinase C subunit alpha (PRKCA) that seg-
regates with AD in five families. All three AD-linked PRKCAmutations
displayed increased catalytic activity (by live imaging) versus wild-type
PRKCA, andpotentiated the ability ofAβ to suppress synaptic activity in
hippocampal slices.42 It will be interesting to determinewhethermuta-
tions in PRKCH have similar aberrant effects on receptor activity.
The three other genes implicated in the spatial clustering–based
analyses included C2CD3, which encodes the C2 domain containing 3
centriole elongation regulator that is expressed at relatively high lev-
els in the brain. Mutations in human C2CD3 cause skeletal dysplasia,
caused by defective assembly of the primary cilium, a microtubule-
based cellular organelle involved in developmental signaling.43 KIF2A
encodes the kinesin family member 2A, which is required for normal
mitotic spindle activity and normal brain development, most likely via
its ATP dependent MT-depolymerase activity.44 Like C2CD3, KIF2A
has also been implicated to affect ciliogenesis, relating to its role
in the cell cycle. KIF2A-related cortical development defects have
been attributed to decoupling between ciliogenesis and cell cycle.44 A
KIF2A His321Asp missense mutation was identified in a subject with
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defective cortical development owing to impairment of KIF2A micro-
tubule depolymerase activity.45 Several members of the kinesin family
are overexpressed in the brains of ADpatients,46 andKIF2A expression
is specifically upregulated in axons, spinal neurons, and oligodendro-
cytes adjacent to spinal cord injuries47 Finally,APC encodes theAdeno-
matosis Polyposis Coli Regulator of WNT Signaling Pathway (as a neg-
ative regulator) and serves as a major tumor suppressor. TheWNT sig-
naling pathway plays an important role in the development of the cen-
tral nervous system, including axonal pathfinding and synaptic plastic-
ity, and has been linked to AD pathogenesis.48 Aβ neurotoxicity in AD
has been reported to downregulateWNT signaling,49 andWNT signal-
ing, in turn, has been shown to regulate β-secretase cleavage of APP.50
Collectively, these findings indicate that inhibition of WNT signaling
mayplay a role in the generation andneurotoxicity ofAβ. ThusAPCmay
influence AD neuropathogenesis via regulation of the WNT signaling
pathway.
In addition to these four loci, an additional five candidate regions
were identified in the secondary analyses, based on the top meta-
analysis results (P < 5×10–5; Table 2b). These included LHX9, NALCN,
CTNNA2, SYTL3, and CLSTN2. LHX9 is a LIM homeobox gene fam-
ily member and is involved in the development of the forebrain.51
This gene has also exhibited genetic association with “self-reported
educational attainment.”52 NALCN encodes a voltage-gated sodium
and calcium channel that is expressed in neurons. Of interest, the
calcium-sensing receptor, CaSR, which has been reported to regulate
NALCN, has been previously implicated as an important signaling
molecule in AD.53 CTNNA2 encodes the neural version of α-catenin
(αN-catenin), a mechano-sensing protein that links cadherins with the
cytoskeleton; as such, they are required for proper neuronal migration
and neuritic outgrowth.54 SYTL3 encodes the Rab effector protein,
synaptotagmin-like 3, which plays a role in vesicle trafficking,55 and
has been genetically associated with lipoprotein (a) levels.56 CLSTN2
encodes Calsyntenin 2, which modulates calcium-mediated postsy-
naptic signaling in the brain. Absence of CLSTN2 impairs synaptic
complexes in mice,57 and has been associated with episodic memory
function in human subjects.58
Pathway analyses based on our highlighted rare variant–associated
genes, emphasize functional roles in neuroplasticity, synaptic function
and integrity, axonal maintenance, neuronal development, and heart
tissue development. In contrast, genes identified through common-
variant associations by GWAS have beenmore involvedwith pathways
linked to immune-system response, lipid metabolism, and Aβ depo-
sition. This stark difference in enrichment profiles may represent an
essential contribution of rare variants to the development of AD based
moreonneuronal and synaptic function. This finding is further substan-
tiated by examining our SNV-associated genes and published common
AD-associated genes for cell-specific biases in expression. We found
that hippocampal CA1 neuronswere significantly enriched for our rare
signature,whereas commongenes fromADGWAShaveprimarily high-
lighted microglia as the likely primary cell type of effect (Figure 7).
Synaptic loss and disruption of neuronal plasticity is considered as an
early event in AD pathology.59 A recent study proposing tau pathology
as one of the initial factors in LOAD, suggests that selected pyramidal
cells are particularly vulnerable to calcium signaling disruption.60 Aβ
can directly affect synaptic integrity and also alter calcium homeosta-
sis.Our findings suggest that the rare-variant genetic profile could trig-
ger an early stage calcium dysregulation event in line with the Calcium
Hypothesis.61
Using whole-genome sequencing, we have performed a whole-
genome global screen to search for association of rare variants with
AD. It is noteworthy that our most significantly SNV-associated gene,
LINC00298, is non-coding and of unknown function. Furthermore, all
nine regions of the genome we have identified to be associated with
AD risk, overlap with regulatory annotations, of which four are signifi-
cantly enriched. Thus our study emphasizes the importance of focusing
on the non-coding part of the genome for a better understanding of the
genetic and functional basis of Alzheimer’s disease.
Themethodologies applied and the results obtained are notwithout
limitations. First and foremost, we note that the size (n∼2300) of the
discovery sample is relatively small compared to common-variant
GWAS in the field. This is due to the limited availability of samples (ie.,
multiplex AD families) and funds (ie, costs for generatingWGS data are
still 1-2 orders of magnitude higher than for common-variant GWAS,
which rely on microarray-based genotype calls). This comes at the
price of reduced statistical power (Supplementary Table 22), which we
addressed by adjusting the discovery and meta-analysis significance
thresholds. As a result, our top findings showP-values ranging between
≈0.01 and ≈8×10–6, which is still almost two orders of magnitude
above a recommended threshold (P < 1×10–8) for rare variant–based
studies in European-based samples.62 We carefully selected sugges-
tive P-value thresholds to balance our ability to detect novel rare
variants while keeping the false-positive rate under control. We tried
to alleviate the limitation of low discovery power by utilizing validation
data from an independent case-control WGS data set (NIA ADSP),
but all of the main findings highlighted here should be considered
preliminary until validated in additional data sets. Eventually, only the
generation and analysis of additional data sets, specificallyWGS, inves-
tigating these and other rare variants in relation to AD susceptibility
will allow us to distinguish true from false-positive findings.
Second, most variants highlighted to be associated with AD risk in
our analyses are located innon-coding regionsof thegenome.Although
this is tobeexpectedgiven theproportionsof coding (∼2%) versusnon-
coding (≈98%) sequence variation in humans, it aggravates efforts to
validate and functionally annotate our top findings. However, efforts
like ENCODE,63 the NIH Epigenomics Roadmap Consortium,64 or the
International Human Epigenome Consortium65 continue to provide
compelling evidence that an increasing fraction of disease-associated
variation maps to the regions between genes, providing a strong argu-
ment for using whole-genome in addition to whole-exome approaches
to capture the full rare-variant architecture underlying AD.
Finally, unlike genetic association analyses in case-control set-
tings, our family-based approach is robust against common genetic
confounders due to population substructure. However, given the
fact that more than 80% of our discovery family–based sample were
individuals of European ancestry, we limited our replication sample to
individuals of the same ancestry. Family-based and case-control data
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sets consisting of subjectswith non-European ancestry are smaller and
likelymore diverse. In addition, effect sizesmight vary among different
populations. Thus future efforts are necessary to expand AD WGS
sequencing and analysis in samples of non-European ancestries.
In summary, here, we describe the first WGS-based rare-variant
association study in AD, and highlight several novel variants and
regions found to be associated with disease risk. Subsequent func-
tional annotation assessments imply several molecular pathways to
be relevant in AD based on rare variant analysis, for example, neu-
ronal development and synaptic integrity. This contrasts with innate
immune, amyloid, and lipid pathways previously implicated by network
analyses of AD GWAS based on common variants. Together with the
results of common-variant AD risk GWAS, our study highlights several
novel promising routes of AD research and provides new potential tar-




The discovery cohort was composed of twoWGS familial cohorts with
1393 (NIMH; AD: n = 966) and 854 (NIA ADSP families; AD: n = 543)
individuals. A subject was considered to be affected if he/she was
included in these categories: “definite AD,” “probable AD,” or “possible
AD.” Unaffected subjects were taken from one of the following cate-
gories: no dementia (667 subjects), suspected dementia (46 subjects)
or non-AD dementia (10 subjects). It is important to note that NIA
ADSP families by design did not include individuals with two APOE ε4
alleles. Because our discovery cohort consisted mostly of individuals
of European ancestry, we used amatching subset (non-Hispanic whites
[NHW]) from the replication cohort (NIA ADSP unrelated, n = 1669).
A total of 564 individuals (AD: n = 307) were obtained with RNA-
Seq data in the temporal cortex fromMayo Clinic Alzheimer’s Disease
Genetics Studies (MCADGS66). All data sets are described in Supple-
mentary Table 1.
4.2 Whole-genome sequencing methods
Plated DNA was obtained from the Rutgers Cell Repository and
sent to Illumina Inc (San Diego, CA, USA) and used to create short-
insert paired-end libraries. Paired-end libraries are manually gener-
ated from 500 ng to 1 ug of gDNA using the Illumina TruSeq DNA
Sample Preparation Kit. Samples are fragmented and libraries were
size-selected targeting 300 bp inserts and sequenced using the HiSeq
2000 System. Illumina-provided BAM files were re-aligned to the
human reference genome (GRh38) with bwa-mem67 (v0.7.7, default
parameters). Reads were marked for duplication using samtools68
(v0.1.19). Germline variants were jointly called for each family using
FreeBayes69 (v0.9.9.2-18) and GATK70 (v3.0) best practices method71
as part of the bcbio-nextgenworkflow72 before being squared-off with
bcbio.recall73 across the whole cohort to distinguish reference calls
from no variant calls. Library and read quality was assessed using
FastQC (v0.10.174 and Qualimap75 (v0.7.1). Variant calls in vcf format
for the NIA ADSP cohort were obtained from the National Institute on
Aging Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS)
under accession number NG00067.
4.3 Quality control of WGS-derived variant calls
We first performed individual-based quality control. Based on geno-
typing rate and inbreeding coefficient, we removed three outliers in
the NIMH data set. Further 12 duplicates and 24 individuals with
wrong family assignments, as per estimated identity by descent (IBD)
sharing, were removed as well (Supplementary Table 23). One thou-
sand three hundred ninety-three clean individuals from NIMH were
combined with 854 individuals from NIA and analysis was performed
only on variants present in both data sets. This was done to ensure
a consistent discovery data set for region-based rare-variant analysis.
Next, family-based discovery data sets were filtered for monomorphic
variants, singletons, variants with a missingness rate higher than 5%,
Mendelian errors, and variants that had aHardy-Weinberg equilibrium
P < 1×10–8. Only variants that had a filter “PASS” in the vcf file were
included in the analysis.
In the case-control replication data sets, variant-based filtering was
performed as in family-based data sets, that is, monomorphic vari-
ants, singletons, variants with a missingness rate higher than 5%, and
variants that had a Hardy-Weinberg equilibrium P < 1×10–8 were
excluded. Only variants that had a filter “PASS” in the vcf file were
included in the analysis. We kept only unrelated individuals of Euro-
pean ancestry in order to closely match our discovery dataset popu-
lation. Principal components were calculated based on rare variants
using the Jaccard index.76 Outliers based on principal components
were excluded.
4.4 External minor allele frequency reference
dataset (gnomAD)
We have downloaded v3.0 of the Genome Aggregation database
(gnomAD),12 which included 71,702 whole genomes (32,399 non-
Finnish European). For minor allele frequency (or MAF) we used the
AFNFE field, which corresponds to allele frequency in the non-Finnish
European population. Variantswere considered rare if AFNFEwas less
than 1% ormore than 99%.
4.5 Single-variant association analyses
In the family-based discovery data sets we used the FBAT Toolkit14
to perform association analysis on variants seen in at least one infor-
mative family in combined NIMH/NIA data set. We used an offset of
0.15, which corresponds approximately to the population prevalence
1522 PROKOPENKO ET AL.
of disease. Although sample preparation and sequencing for NIMH
and NIA families were performed at multiple centers, members of the
same family were always sequenced at the same center, which mini-
mizes the impact of batch effects on the FBAT approach. QQplots (Fig-
ures 2 and 5) show no evidence of batch effects leading to inconsistent
Mendelian transmission patterns.
In the case-control replication data sets we performed a logis-
tic regression (with option “firth-fallback”) for case/control status as
implemented in PLINK 2.77 We included sex, age, sequencing center,
and 5 Jaccard principal components76 with standardized variance as
covariates. We next performed a fixed-effects meta-analysis of two
data sets. The meta-analysis was performed with the METAL toolkit78
with a sample-size–based weighting scheme. Quantile-quantile plots




In the family-based discovery data set, we systematically grouped the
whole-genome sequencing data into non-overlapping regions using
a spatial-clustering approach. Briefly, variants are grouped together
into regions assuming an inhomogeneous Poisson process based on
the physical positions of single variants and include only those that
are in proximity to one another. We included only variants seen in at
least two families. After we partitioned the chromosomes into non-
overlapping windows, there were 232,188 regions with a mean num-
ber of 45 variants in each region (median = 22). We ran FBAT-RV,79 a
multimarker testwithMAFweighting,whichwasused to test identified
non-overlapping regions in the combined family-based data set. First,
only rare variants were included in the analysis. Next, we performed a
second run including all variants.
In the case-control replication data sets, joint variant testing was
performed on rare variants using the burden test as implemented in
the SKAT package.80We next used SKAT-RC81 to incorporate all vari-
ants with no MAF threshold. We used the same set of covariates as in
the single-variant analysis. For consistency, we tested the same non-
overlapping regions, whichwere identified in the combinedNIMH/NIA
data set. This allowed us to perform a meta-analysis of the identified
regions, using Fisher’s combined probability test.
4.7 Power calculations
We have calculated power to detect a significant association of a vari-
ant with a MAF of 0.01 for a range of effect sizes (Supplementary
Table 22). Alpha level was set to 0.0005, which corresponds to our dis-
covery P-value threshold, and prevalence was set to 0.15. We used
PBAT82 to estimate power in a family-based study design and assumed
605 families with two affected and one unaffected offspring and miss-
ing parents, which approximates the structure in the real data set. We
used the GAS Power Calculator83 to estimate power in a case-control
design. We assumed a sample size of 4000 with a case to control ratio
of 3:2, which approximates a sample size of our meta-analysis.
As expected, this revealed that we only had modest power in the
WGS discovery sample for variants with an odds ratio (OR)≈4.5 (50%)
and high power for variants with an OR ≈6 (82%). We had reasonable
power to detect lower-effect alleles in the combined “meta-analysis”
arm of our study (87% for variants exerting anOR= 2.5).
4.8 Burden association testing in exons
To assess the associations described inHolstege et al.,20 we closely fol-
lowed their filtering scheme.We used LOFTEE and REVEL to annotate
exonic variants and create deleteriousness categories. We tested only
genes in their top categories from their table 1. Burden of rare vari-
ants was tested using FBAT-RVwith EOAD cases (age at onset<= 65)
coded as 1, LOAD cases coded as 2, and controls coded as−0.2.
4.9 Variant and regional association with genes
Disease-associated variants are often assigned to genes by their prox-
imity, where only genes overlapping or closely flanking the reported
SNVs are considered. The overlap-only strategy excludes other poten-
tially causal genes within the associated haplotype. However, expand-
ing gene association to include non-overlapping SNVs or regions is
complicated by the current diversity and inconsistency of annotation
for non-coding regions of the genome. As regulatory regions proximal
and distal to a gene are becoming extensively annotated,84 we have
leveraged the functional significanceof sets of cis-regulatory regions of
the vertebrate genome. We applied The Genomic Regions Enrichment
of Annotations Tool (GREAT) to leverage functional cis-regulatory
regions identified by localized measurements of DNA-binding events
across the genome.85 GREAT assigned additional genes to both SNVs
and regions when applied to loci with no direct gene overlap.
4.10 Differential gene expression
A mixed-effect linear regression was performed on the RNA-Seq out-
put with Bioconductor (v3.7) using CQN86 and limma87 adjusting for
clinical and technical variations. A multiple testing correction was
applied.
4.11 Annotation and geneset enrichment
Prioritized variants and regions were annotated for relationships
to eQTLs (GTEX88), CpG islands, DNase hypersensitivity, RNA gene
locations, and RNA-binding sites (UCSC89), enhancers, promoters,
transcription start sites, transcription factor binding sites, and other
regulatory features (Ensembl90; FANTOM591), histone marks and
GC-content (GWAVA92), 3D genomic interactions and open chromatin
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(3DSNP93), cell-specific enhancers (INFERNO94), and the Illumina
bodyMap2 transcriptome (GSE30611).
4.12 Regulatory enrichment within
spatial-clustering/region-based association
To test whether the top regions of interest were overpopulated with
regulatory annotations, we computed 103 random permutations per
region across the genome of the same length to count the number
of overlapping annotations. These regions were restricted to regions
with similar numbers of genes. A Fisher exact test was used to com-
pare annotations within the top leading regions against these per-
muted regions.Multiple testing correctionwas applied for every region
x annotation that was tested.
4.13 Cell-specific enrichments
We performed Expression Weighted Cell Type Enrichment with
EWCE21 using mouse single-cell transcriptomic data from the cortex
and hippocampus.95 EWCE aims to identify the cellular origins of a dis-
order by examining where a disease-associated gene list is primarily
expressed and testing this against a distribution obtained from 10,000
permutations of random lists. We selected four gene lists to be tested:
the leading SNV/region-associated genes from Tables 1 and 2 (n = 5),
SNV-associated genes (Pmeta < 0.01; n= 185), region-associated genes
(Pmeta <0.0005; n=55), andpublishedcommon-variantAD-associated
genes22 (n = 32). Seventy-eight percent of these genes had a mouse
homolog, which was then used in the analysis.
4.14 Functional enrichment analysis for
associated genes
Functional enrichment for the SNV- and regional-associated genes
or for genes found to be co-expressed with LINC00298, was per-
formed via the Metascape server,96 which applies the hypergeomet-
ric test97 and Benjamini-Hochberg P-value correction algorithm98 to
identify terms (all GOontologies, Reactome, andKEGGpathways) that
contain a statistically greater number of genes in common with an
input list than expected by chance. Enriched terms were filtered at an
FDR<= 0.1.
4.15 Network relationships with known AD genes
First, we set out to understand novel but direct relationships between
genes associated with our identified variants and regions and already
published Alzheimer’s-associated genes. These known Alzheimer’s
genes were selected from a recently published review22 and include
genes that cause familial forms of the disease (eg, APP, PSEN1,
and PSEN2) as well as genes that have the highest association in
GWAS.3,5,9,99,100 We used the StringDB101 protein-protein interac-
tion resource using only identified protein-protein interactions. Using
this background that agglomerates protein-protein interaction data
sets, combining evidence from several experimentally derived, curated
interaction databases, we identified direct (curated AD genes directly
interactingwith our associated genes) associations in a global network,
which contained 22 known AD genes, 73 regional-associated genes,
and 59 SNV-associated genes (Supplementary Table 24). This network
was reviewed for direct interactions between known AD genes and
SNV/regional-associated genes. Genes related to each other in this
manner were then visualized using Cytoscape.102 Genes in this net-
work co-expressed with LINC00298were highlighted when correlated
in expression as defined according to pre-calculated correlations avail-
able at the lncHUB server103 (Supplementary Table 25). The server
provides gene-lncRNA Pearson correlation computed from 11,284
TCGA normalized samples processed by recount241 .
Functional enrichmentwithin this networkwas performedusing the
remote StringDB server linked to Cystoscape “String App Enrichment
function,”104 producing enrichments using the hypergeometric test,
with P-values corrected for multiple testing using the method of Ben-
jamini and Hochberg in known molecular pathways and GO terms as
described in Frenceschini et al.105 Enriched GO/pathway terms were
considered at an FDR < = 0.05. Genes from our study and known
Alzheimer’s genes coding for proteinsdirectly interactingwithproteins
identified by genes from Table 1 and Table 2 were examined for com-
monenrichment and grouped around the geneswehighlighted in these
tables into functional clusters where possible. Genes from our study
or known AD genes that show protein-protein interaction links with
Table 1- and Table 2-identified genes were grouped most closely in the
common annotation clusters. The top GO enrichment classes (nervous
system development and generation of neurons) were annotated to nodes
using the String enrichment color palette function to produce highlighted
node borders. Immune-related functions that showed enrichment for
currently known AD-related genes were used to group both known
ADgenes and regional-associated and SNV-associated into annotation
clusters.
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